Phacomatosis

Abstract

Neurocutaneous syndromes are a group of genetically transmitted diseases with skin lesions, of which more than 60 types have been defined and are of ectodermal origin. Except for ataxia-telangiectasia, all are autosomal dominant. These syndromes are significant in neuro-oncology because they create a predisposition to cancer and cause the formation of a wide range of tumors, from hamartomas to malignant tumors. There is no curative treatment in these syndromes; their treatments are symptomatic and surgical treatment is preferred only due to severe neurological deficits and increased mass effect. This article aims to re-summarize the clinical features of common neurocutaneous syndromes in light of current developments.

Keywords

• Phakomatosis
• neurofibromatosis
• optic glioma
• von hippel-lindau
• tuberosklerosis

Ethical Statement

There is nothing to declare

Fakomatozlar

Abstract

Nörokütanöz sendromlar ektodermal kökenli 60’ın üzerinde tipi tanımlanmış olan cilt bulguları ile bulunan genetik geçişli bir grup hastalıktır. Ataksi-telenjiektazi hariç hepsi otozomal dominant geçişlidir. Bu sendromlar kanser yatkınlığı oluşturdukları ve hamartomlardan malign tümörlere uzanan geniş bir yelpazede tümörlerin oluşumuna neden oldukları için nöroonkolojide son derece önemlidirler. Bu sendromlarda küratif tedavi bulunmamaktadır, tedavileri semptomatiktir ve cerrahi tedavi ancak ciddi nörolojik defisit ve artmış kitle etkisi sebebi ile tercih edilmektedir. Bu yazının amacı sık görülen nörokütanöz sendromların klinik özelliklerini güncel gelişmeler ışığında yeniden özetlemektir.

Keywords

• fakomatozlar
• nörofibromatozis
• optik gliom
• von hippel-lindau
• tuberoskleroz

Ethical Statement

Makale yazarlarının çıkar çatışması beyanı yoktur.

References

1. 1.Swarup MS, Swati Gupta S, Singh S, Prakash A, Mehndiratta A, Garg A. Phakomatoses: A pictorial review Indian J Radiol Imaging 2020;30(2):195–205. doi: 10.4103/ijri.IJRI_497_19
2. 2.Bulduk EB, Börçek AÖ. Nörokütanöz sendromlar-fakomatozlar. Türk Nöroşir Derg 2017; 27(2):131-6.
3. 3.Işık N, Baysal B. Fakomatozlar. In: Yılmaz E (ed). TemelNöroşirurji 1st edition. Ankara: Türk Nöroşirurji DerneğiYayınları: 2023. 2011-26
4. 4.Becker B, Strowd RE 3rd. Phakomatoses. Dermatol Clin.2019;37(4):583-606. doi: 10.1016/j.det.2019.05.015.
5. 5.Korf BR. Neurofibromatosis. Handb Clin Neurol.2013;111:333-40. doi: 10.1016/B978-0-444-52891-9.00039-7.
6. 6.Sabeti S, Ball KL, Bhattacharya SK, Bitrian E, Blieden LS,Brandt JD, Burkhart C, Chugani HT, Falchek SJ, Jain BG, Juhasz C, Loeb JA, Luat A, Pinto A, Segal E, Salvin J, KellyKM. Consensus Statement for the Management and Treatment of Sturge-Weber Syndrome: Neurology, Neuroimaging, and Ophthalmology Recommendations. Pediatr Neurol. 2021;121:59-66. doi: 10.1016/j.pediatrneurol.2021.04.013.
7. 7.Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA,Berman Y, Blakeley J, Babovic-Vuksanovic D, Cunha KS, Ferner R, Fisher MJ, Friedman JM, Gutmann DH, Kehrer-Sawatzki H, Korf BR, Mautner VF, Peltonen S, Rauen KA, Riccardi V, Schorry E, Stemmer-Rachamimov A, Stevenson DA, Tadini G, Ullrich NJ, Viskochil D, Wimmer K, Yohay K. International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC), Huson SM, Evans DG, Plotkin SR. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: An international consensus recommendation. Genet Med 2021;23:1506-13.
8. 8.Kehrer-Sawatzki H, Kluwe L, Salamon J, Well L, Farschtschi S, Rosenbaum T, Mautner VF. Clinical characterization of children and adolescents with NF1 microdeletions. Childs NervSyst 2020;36:2297-2310.

9. 9.Ruggieri M, Polizzi A, Marceca GP, Catanzaro S, Praticò AD,Di Rocco C. Introduction to phacomatoses (neurocutaneous disorders) in childhood. Childs Nerv Syst 2020;36(10):2229-68.
10. 10.Pinti E, Nemeth K, Staub K, Lengyel A, Fekete G, Haltrich I.Diagnostic difficulties and possibilities of NF1-like syndromesin childhood. BMC Pediatr 2021;21:331.
11. 11.Little H, Kamat D, Sivaswamy L. Common Neurocutaneous Syndromes. Pediatr Ann. 2015;44(11):496-504. doi: 10.3928/00904481-20151112-11.
12. 12.Erdogan H., A. Karaoglan. Nörofibromatozis Tip 2. Türk Nöroşirürji Dergisi 2016;26(Ek Sayı 1): 92-100
13. 13.Klingler JH, Gläsker S, Bausch B, Urbach H, Krauss T, Jilg CA, Steiert C, Puzik A, Neumann-Haefelin E, Kotsis F,Agostini H, Neumann HPH, Beck J: Hemangioblastoma and von Hippel-Lindau disease: Genetic background, spectrum ofdisease, and neurosurgical treatment. Childs Nerv Syst2020;36(10):2537-52
14. 14.Perlman S. Von Hippel-Lindau disease and Sturge-Weber syndrome. Handb Clin Neurol. 2018;148:823-826. doi: 10.1016/B978-0-444-64076-5.00053-3.
15. 15.Russo C. Nastro A, Cicala D, De Liso M, Covelli EM, CinalliG.Neuroimaging in tuberous sclerosis complex. Childs NervSyst 2020;36:2497–2509.
16. 16.Frassanito P, Noya C, Tamburrini G. Current trends in the management of subependymal giant cell astrocytomas in tuberous sclerosis. Childs Nerv Syst 2020;36:2527-36